Myriad Genetics, Inc. (MYGN)
4.29
+0.20
(+4.89%)
USD |
NASDAQ |
May 08, 16:00
4.285
0.00 (0.00%)
After-Hours: 20:00
Myriad Genetics EPS Diluted (Quarterly) : -0.3639 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Celldex Therapeutics, Inc. | -1.182 |
| Plus Therapeutics, Inc. | -1.03 |
| Perspective Therapeutics, Inc. | -0.5043 |
| Atossa Therapeutics, Inc. | -1.112 |
| AVITA Medical, Inc. | -0.3825 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -34.10M |
| Revenue (Quarterly) | 200.40M |
| Total Expenses (Quarterly) | 234.50M |
| Enterprise Value | 492.28M |
| Gross Profit Margin (Quarterly) | 64.72% |
| Profit Margin (Quarterly) | -17.02% |
| Earnings Yield | -100.6% |
| Normalized Earnings Yield | -43.32 |